checkAd
    Startseite > Aktien > Vir Biotechnology > Nachrichten
    Vir Biotechnology Aktie
    10,390
     
    USD
    +2,87 %
    +0,290 USD
    Letzter Kurs 02:00:00 Nasdaq
    10,380
     
    USD
    600 STK
    Geldkurs 30.05.24
    10,400
     
    USD
    3.700 STK
    Briefkurs 30.05.24
    ISIN: US92764N1028 · WKN: A2PS0P · SYM: VIR · USA

    Neueste Nachrichten

    Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    29.05.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
    29.05.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
    23.05.24 · Business Wire (engl.) · Vir Biotechnology
    Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
    22.05.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
    21.05.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
    02.05.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
    30.04.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
    18.04.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
    11.04.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
    05.03.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
    23.02.24 · Business Wire (engl.) · Vir Biotechnology
    Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    22.02.24 · Business Wire (engl.) · Vir Biotechnology